File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Epigallocatechin-3-gallate local pre-exposure application prevents SHIV rectal infection of macaques article

TitleEpigallocatechin-3-gallate local pre-exposure application prevents SHIV rectal infection of macaques article
Authors
Issue Date2018
Citation
Mucosal Immunology, 2018, v. 11, n. 4, p. 1230-1238 How to Cite?
AbstractEpigallocatechin-3-gallate (EGCG), a natural and major ingredient of green tea, has been shown to have anti-inflammation and anti-HIV-1 properties. We demonstrated that the intrarectal administration of EGCG could protect rhesus macaques from repetitive, intrarectal challenges with low-dose SHIVSF162P3N. This protection has a per-exposure risk reduction of 91.5% (P = 0.0009; log-rank test) and a complete protection of 87.5% (P < 0.001; Fisher's exact test). All protected animals showed no evidence of systemic and mucosal SHIV infection as demonstrated by the absence of viral RNA, DNA and antibodies. In contrast, all controls became infected after repeated SHIV challenges (a median of 2.5 times, range of 1-8 times). Mechanistically, EGCG could block the binding of HIV-1 gp120 to CD4 receptor and suppress the macrophage infiltration/activation in the rectal mucosa of macaques. These data support further clinical evaluation and development of EGCG as a novel, safe and cost-effective microbicide for preventing sexual transmission of HIV-1.
Persistent Identifierhttp://hdl.handle.net/10722/321794
ISSN
2023 Impact Factor: 7.9
2023 SCImago Journal Rankings: 3.320
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, J. B.-
dc.contributor.authorLi, J. L.-
dc.contributor.authorZhuang, K.-
dc.contributor.authorLiu, H.-
dc.contributor.authorWang, X.-
dc.contributor.authorXiao, Q. H.-
dc.contributor.authorLi, X. D.-
dc.contributor.authorZhou, R. H.-
dc.contributor.authorZhou, L.-
dc.contributor.authorMa, T. C.-
dc.contributor.authorZhou, W.-
dc.contributor.authorLiu, M. Q.-
dc.contributor.authorHo, W. Z.-
dc.date.accessioned2022-11-03T02:21:29Z-
dc.date.available2022-11-03T02:21:29Z-
dc.date.issued2018-
dc.identifier.citationMucosal Immunology, 2018, v. 11, n. 4, p. 1230-1238-
dc.identifier.issn1933-0219-
dc.identifier.urihttp://hdl.handle.net/10722/321794-
dc.description.abstractEpigallocatechin-3-gallate (EGCG), a natural and major ingredient of green tea, has been shown to have anti-inflammation and anti-HIV-1 properties. We demonstrated that the intrarectal administration of EGCG could protect rhesus macaques from repetitive, intrarectal challenges with low-dose SHIVSF162P3N. This protection has a per-exposure risk reduction of 91.5% (P = 0.0009; log-rank test) and a complete protection of 87.5% (P < 0.001; Fisher's exact test). All protected animals showed no evidence of systemic and mucosal SHIV infection as demonstrated by the absence of viral RNA, DNA and antibodies. In contrast, all controls became infected after repeated SHIV challenges (a median of 2.5 times, range of 1-8 times). Mechanistically, EGCG could block the binding of HIV-1 gp120 to CD4 receptor and suppress the macrophage infiltration/activation in the rectal mucosa of macaques. These data support further clinical evaluation and development of EGCG as a novel, safe and cost-effective microbicide for preventing sexual transmission of HIV-1.-
dc.languageeng-
dc.relation.ispartofMucosal Immunology-
dc.titleEpigallocatechin-3-gallate local pre-exposure application prevents SHIV rectal infection of macaques article-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/s41385-018-0025-4-
dc.identifier.pmid29855550-
dc.identifier.scopuseid_2-s2.0-85047953584-
dc.identifier.volume11-
dc.identifier.issue4-
dc.identifier.spage1230-
dc.identifier.epage1238-
dc.identifier.eissn1935-3456-
dc.identifier.isiWOS:000438121300020-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats